[1]阚通,秦永文.二尖瓣反流诊治进展[J].心血管病学进展,2015,(6):686-690.[doi:10.3969/j.issn.1004-3934.2015.06.008]
　KAN Tong,QIN Yongwen.Recent Progress in Diagnosis and Treatment of Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2015,(6):686-690.[doi:10.3969/j.issn.1004-3934.2015.06.008]
点击复制

二尖瓣反流诊治进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2015年6期
页码:
686-690
栏目:
综述
出版日期:
2016-06-20

文章信息/Info

Title:
Recent Progress in Diagnosis and Treatment of Mitral Regurgitation
作者:
阚通; 秦永文
第二军医大学附属长海医院心血管内科, 上海 200433
Author(s):
KAN Tong;  QIN Yongwen
Department of Cardiology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China
关键词:
二尖瓣反流;  二尖瓣;  诊断;  治疗结果
Keywords:
mitral regurgitation;  mitral valve;  diagnosis;  treatment outcome
分类号:
R542.5
DOI:
10.3969/j.issn.1004-3934.2015.06.008
文献标志码:
A
摘要:
影响二尖瓣关闭功能的疾病都可以导致二尖瓣反流。轻度二尖瓣反流患者仅有轻微劳力性呼吸困难,重度二尖瓣反流症状严重,降低患者的生存时间。目前依据病因可将二尖瓣反流分为原发性二尖瓣反流和继发性二尖瓣反流,这两种二尖瓣反流有不同的诊断和治疗原则。现就二尖瓣反流的诊断治疗进展做一综述。
Abstract:
The diseases that affect the function of mitral valve can lead to mitral regurgitation(MR). The patients with mild MR can only feel mild exertional dyspnea and the patients with severe MR can feel severe symptoms, which reduces the patients' survival time. Presently, MR is classified into primary and secondary entities based on the pathogen. The diagnosis and treatment of the primary and secondary MR are quite different. This paper aims to make a comprehensive review about the recent progress in diagnosis and treatment of MR.

参考文献/References:

[1] Trichon BH, Felker GM, Shaw LK, et al. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure[J]. Am J Cardiol,2003,91(5):538-543.
[2] Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community:the emerging role of mitral regurgitation[J]. Circulation,2005,111(3):295-301.
[3] Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation[J]. N Engl J Med,2005,352(9):875-883.
[4] Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study[J]. Lancet,2006,368(9540):1005-1011.
[5] Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease:executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2014,63(22):2438-2488.
[6] Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult[J]. Nat Rev Cardiol,2011,8(3):162-172.
[7] Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community:the emerging role of mitral regurgitation[J]. Circulation,2005,111(3):295-301.
[8] Ling LH, Enriquez-Sarano M, Seward JB, et al. Clinical outcome of mitral regurgitation due to flail leaflet[J]. N Engl J Med,1996,335(19):1417-1423.
[9] Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography[J]. J Am Soc Echocardiogr,2003,16(7):777-802.
[10] Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation[J]. N Engl J Med,2005,352(9):875-883.
[11] Lang RM, Badano LP, Tsang W, et al. EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography[J]. J Am Soc Echocardiogr,2012,25(1):3-46.
[12] Magne J, Mahjoub H, Pierard LA, et al. Prognostic importance of brain natriuretic peptide and left ventricular longitudinal function in asymptomatic degenerative mitral regurgitation[J]. Heart,2012,98(7):584-591.
[13] Witkowski TG, Thomas JD, Debonnaire PJ, et al. Global longitudinal strain predicts left ventricular dysfunction after mitral valve repair[J]. Eur Heart J Cardiovasc Imaging,2013,14(1):69-76.
[14] Pflugfelder PW, Sechtem UP, White RD, et al. Noninvasive evaluation of mitral regurgitation by analysis of left atrial signal loss in cine magnetic resonance[J]. Am Heart J,1989,117(5):1113-1119.
[15] Myerson SG, Francis JM, Neubauer S. Direct and indirect quantification of mitral regurgitation with cardiovascular magnetic resonance, and the effect of heart rate variability[J]. MAGMA,2010,23(4):243-249.
[16] Saiki Y, Kasegawa H, Kawase M, et al. Intraoperative TEE during mitral valve repair: does it predict early and late postoperative mitral valve dysfunction?[J]. Ann Thorac Surg,1998,66(4):1277-1281.
[17] Nemoto S, Hamawaki M, de Freitas G, et al. Differential effects of the angiotensin-converting enzyme inhibitor lisinopril versus the beta-adrenergic receptor blocker atenolol on hemodynamics and left ventricular contractile function in experimental mitral regurgitation[J]. J Am Coll Cardiol, 2002,40(1):149-154.
[18] Ahmed MI, Aban I, Lloyd SG, et al. A randomized controlled phase Ⅱb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation[J]. J Am Coll Cardiol,2012,60(9):833-838.
[19] Tischler MD, Rowan M, LeWinter MM. Effect of enalapril therapy on left ventricular mass and volumes in asymptomatic chronic, severe mitral regurgitation secondary to mitral valve prolapse[J]. Am J Cardiol, 1998,82(2):242-245.
[20] Harris KM, Aeppli DM, Carey CF. Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity[J]. Am Heart J,2005,150(5):1106.
[21] Rowe JC, Bland EF, Sprague HB, et al. The course of mitral stenosis without surgery:ten- and twenty-year perspectives[J]. Ann Intern Med, 1960,52:741-749.
[22] The SOLVD Investigators.Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions[J]. N Engl J Med,1992,327(10):685-691.
[23] van Bommel RJ, Marsan NA, Delgado V, et al. Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk[J]. Circulation, 2011,124(8):912-919.
[24] Detaint D, Sundt TM, Nkomo VT, et al. Surgical correction of mitral regurgitation in the elderly: outcomes and recent improvements[J]. Circulation, 2006,114(4):265-272.
[25] Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease(version 2012)[J]. Eur Heart J,2012,33(19):2451-2496.
[26] Enriquez-Sarano M, Schaff HV, Orszulak TA, et al. Valve repair improves the outcome of surgery for mitral regurgitation. A multivariate analysis[J]. Circulation,1995,91(4):1022-1028.
[27] Gammie JS, O'Brien SM, Griffith BP, et al. Influence of hospital procedural volume on care process and mortality for patients undergoing elective surgery for mitral regurgitation[J]. Circulation,2007,115(7):881-887.
[28] Mehta RH, Eagle KA, Coombs LP, et al. Influence of age on outcomes in patients undergoing mitral valve replacement[J]. Ann Thorac Surg, 2002,74(5):1459-1467.
[29] Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation[J]. N Engl J Med,2011,364(15):1395-1406.
[30] Glower D, Ailawadi G, Argenziano M, et al. EVEREST Ⅱ randomized clinical trial: predictors of mitral valve replacement in de novo surgery or after the MitraClip procedure[J]. J Thorac Cardiovasc Surg,2012,143(4 Suppl):S60- S63.
[31] Mauri L, Foster E, Glower DD, et al. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation[J]. J Am Coll Cardiol,2013,62(4):317-328.
[32] Grasso C, Capodanno D, Scandura S, et al. One- and twelve-month safety and efficacy outcomes of patients undergoing edge-to-edge percutaneous mitral valve repair(from the GRASP Registry)[J]. Am J Cardiol, 2013,111(10):1482-1487.
[33] Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe[J]. J Am Coll Cardiol,2013,62(12):1052-1061.
[34] Rudolph V, Lubos E, Schluter M, et al. Aetiology of mitral regurgitation differentially affects 2-year adverse outcomes after MitraClip therapy in high-risk patients[J]. Eur J Heart Fail,2013,15(7):796-807.
[35] Schillinger W, Hunlich M, Baldus S, et al. Acute outcomes after MitraClip therapy in highly aged patients: results from the German TRAnscatheter Mitral valve Interventions(TRAMI)Registry[J]. EuroIntervention, 2013,9(1):84-90.
[36] Swaans MJ, Bakker AL, Alipour A, et al. Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgical-risk patients[J]. JACC Cardiovasc Interv,2014,7(8):875-881.
[37] Taramasso M, Maisano F, Latib A, et al. Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation[J]. EuroIntervention, 2014,10(6):746-752.

相似文献/References:

[1]阚通,秦永文.二尖瓣关闭不全介入治疗进展[J].心血管病学进展,2016,(1):16.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.005]
　KAN Tong,QIN Yongwen.Recent Progress in Transcatheter Therapy of Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(6):16.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.005]
[2]陈旭东 张逸杰 韦洋.经导管二尖瓣置换治疗原发性二尖瓣反流的研究进展[J].心血管病学进展,2023,(2):137.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.009]
　CHEN XudongZHANG YijieWEI Yang.Transcatheter Mitral Valve Replacement in Primary Mitral Valve Regurgitation[J].Advances in Cardiovascular Diseases,2023,(6):137.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.009]
[3]马浩 张世成 宋仰午 黄思源 赵栋 凤玮.单纯冠状动脉旁路移植术治疗左心室室壁瘤的回顾性队列研究[J].心血管病学进展,2023,(5):465.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.019]
　MA Hao,ZHANG Shicheng,SONG Yangwu,et al.Surgical Effects of Coronary Artery Bypass Grafting Alone for Patients with Left Ventricular Aneurysm:A Retrospective Cohort Study[J].Advances in Cardiovascular Diseases,2023,(6):465.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.019]
[4]王湘 李刚 王水云.合并巨大左心室的心脏瓣膜病治疗现状[J].心血管病学进展,2024,(9):769.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.001]
　WANG Xiang,L I Gang,WANG Shuiyun.Treatment Status of Valvular Heart Disease with Giant Left Ventricle[J].Advances in Cardiovascular Diseases,2024,(6):769.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.001]

备注/Memo

备注/Memo:
作者简介:阚通(1990—),在读硕士,主要从事心血管病介入治疗研究。Email: 871415868@qq.com 通信作者:秦永文(1952—),主任医师,教授,博士,主要从事心血管病介入治疗研究。Email: chqinyw@163.com
更新日期/Last Update: 2016-06-20